Table 4.
Details of Thromboembolism Cases Among Transwomen (n=22)
| Case | Event and ICD-10 code | Age | HT formulation and duration | BMI | PMH/FH or known risks |
|---|---|---|---|---|---|
| 1 | DVT, provoked (I82.90) | 47 | Estradiol valerate IM 10–14 mg Q14 days×3 years | 32.6 | PMH: • Knee surgery 3 weeks |
| 2 | DVT (I82.89) | 60 | Estradiol valerate IM 40 mg Q14 days×3 years | 29.7 | No significant PMH or FH |
| 3 | DVT, provoked (I82.402) | 25 | Estradiol PO 6 mg Qd×2 years followed by: Estradiol valerate IM 20 mg Q14 days×2 years |
41.2 | PMH: • Immobilized×5 weeks before event due to foot injury • Fatty liver disease FH: Mother and Father: HLD, HTN |
| 4 | Thrombophlebitis (I80.9) | 38 | Estradiol 6 mg PO Qd×1 year, Micronized progesterone 100 mg×7 months, 4 years before event followed by: Estradiol valerate 20 mg IM Q14d and×5 years |
27.5 | PMH: • Smoker • Bipolar disease on lamictal and risperidone |
| 5 | Thrombophlebitis and PE, provoked (I26.99) | 58 | Estradiol valerate IM 20 mg Q14d×2 years and androgel 12.5 mg every other day | 30.5 | PMH: • HTN • Abdominal surgery 4 weeks prior • Thrombophlebitis at PICC line site |
| 6 | DVT, provoked (I82.40) | 45 | Estradiol valerate IM 8–20 mg Q7 days×4 years | 34.5 | PMH: • Surgery before TE • Schizoaffective d/o on ziprasidone FH: Multiple family members: HTN and heart disease |
| 7 | Superficial phlebitis (180.9) | 23 | Estradiol 4–6 mg PO Qd×4 months, MPA 2.5 mg Qd×2 months | 28.6 | PMH: • Schizophrenia on Abilify • 1 Day prior injected heroin into affected vein |
| 9 | PE (I26.99) | 55 | 0.6 mg/24 h TD patches weekly×1 year followed by: Estradiol TD 0.2 mg/24 h patch Q 3d and premarin |
28.3 | PMH: • Schizoaffective disorder on Haldol, clozapine and divalproex |
| 10 | DVT (I82.4Z9) | 50 | Estradiol valerate IM 20 mg Q7 days×16 years | 32.2 | PMH: • Hx of DVT |
| 12 | Arterial micro emboli (MCA) (I66.09) | 46 | Estradiol 4–8 mg PO Qd×7 years | 40.8 | No significant PMH or FH |
| 13 | Superficial phlebitis (I80.9) | 38 | Estradiol valerate IM 20 mg Q14 days and premaren 5 mg Qd×5 years | 46.6 | PMH: • IV infusion placed in affected vein 1 week prior |
| 14 | PE, provoked (I26.99) | 38 | Conjugated estrogens 10 mg Qd×4 years followed by: Estradiol PO 6 mg Qd×3 years and MPA 2.5 mg Qd×1 year |
28.4 | PMH: • Ankle surgery 1 month prior |
| 15 | Portal vein thrombosis (I81) | 36 | Estradiol valerate IM 10–20 mg Q 14d×10 years | 29.9 | PMH: • HIV • Seizure disorder on lamictal • Asthma on prednisone |
| 17 | DVT and PE, provoked (I82.90, I26.99) | 37 | Premarin 25 mg Qd×3 months; Progesterone 100 mg Qd×2 months 1 year before incident followed by: Estradiol valerate IM 20 mg Q14 days×7 years |
42.2 | PMH: • HIV • Flight 1 week before DVT |
| 18 | Bilateral PEs, DVT (I82.90, I26.99) | 72 | Estradiol valerate 4–12 mg IM Q7 days×7 years | 32.9 | PMH: • Underlying malignancy diagnosed after incident (colon cancer) |
| 19 | Acute DVT, muscle spasm (I82.4Z) | 29 | Estradiol valerate IM Q14d×3 years, Progesterone 100 mg Qd×6 months | 35.1 | PMH: • Smoker (1 ppd) • Depression on Geodon |
| 20 | Acute DVT of legs, I82.40 | 51 | Estradiol valerate IM 8 mg Q7d×2 months | 48.1 | PMH: • Schizophrenia on risperidone • Former smoker, HTN |
| 21 | Inferior vena cava syndrome (187.1) | 24 | Estradiol TD 0.1 mg/24 h twice a week×1 year Progesterone 100 mg Qd×10 months |
25.8 | No significant PMH or FH |
| 22 | Right leg pain, DVT (I82.4) | 34 | Estradiol valerate IM 40 mg Q14 days×10 years | 26.6 | FH: Mother HTN |
FH, family history; DVI, deep vein thrombosis; PMH, patient medical history.